Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LSL Pharma Group (TSXV:LSL) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
LSL Pharma Group's Enterprise Value for the quarter that ended in Mar. 2026 was C$94.88 Mil.
LSL Pharma Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSL Pharma Group EV-to-EBIT Related Terms
LSL Pharma Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for LSL Pharma Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, LSL Pharma Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LSL Pharma Group EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, LSL Pharma Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where LSL Pharma Group's EV-to-EBIT falls into.
LSL Pharma Group's current Enterprise Value is C$87.91 Mil.
LSL Pharma Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSL Pharma Group (TSXV:LSL) has a EV-to-EBIT of -34.91 as of Jul. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on LSL Pharma Group and its competitors. According to the industry distribution chart, LSL Pharma Group ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is LSL Pharma Group's EV-to-EBIT too high?
LSL Pharma Group's current EV-to-EBIT is -34.91. Based on the distribution chart, LSL Pharma Group ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, LSL Pharma Group has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does LSL Pharma Group's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, LSL Pharma Group ranks #999999 out of 690 companies for EV-to-EBIT. This places LSL Pharma Group in the lower half of its industry. The industry median EV-to-EBIT is 15.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.46, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on LSL Pharma Group and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LSL Pharma Group's current EV-to-EBIT is -34.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LSL Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, LSL Pharma Group (TSXV:LSL) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.73, compared to a current price of C$0.36 — trading 51.4% below its estimated fair value. The current EV-to-EBIT is -34.91. LSL Pharma Group's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For LSL Pharma Group (TSXV:LSL), the current EV-to-EBIT is -34.91 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LSL Pharma Group (TSXV:LSL) Overvalued in 2026?
Based on GuruFocus' analysis, LSL Pharma Group stock appears to be undervalued.
The current stock price of C$0.36 is trading 51.4% below its estimated GF Value™ of C$0.73.
GuruFocus considers LSL Pharma Group to be Possible Value Trap.
Key valuation signals for TSXV:LSL:
EV-to-EBIT: -34.91
GF Value™: C$0.73 vs. price of C$0.36 (51.4% below fair value)
No single metric tells the full story. See the TSXV:LSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LSL Pharma Group Inc develops, manufactures and commercializes sterile pharmaceutical products, cosmetic products and natural health products. It operates in three segments CMO activities include four operating entities LSL Laboratory, Dermolab, Du-Var, and VSI; Integrated Eye-care pharmaceutical company which includes sterile Eye-care manufacturing operation; and Private Label Business includes Juno OTC which commercializes pharmaceutical products with a focus on private label, over the counter (OTC) products. It derives majority of revenue from CMO activities segment.
48GF Score
Get the complete analysis for TSXV:LSL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:LSL has been successfully added to your 
